IP Library Granted Patent US 8,617,540
Granted Patent B2
US 8,617,540 · App. 12/760,673 · Granted Dec 31, 2013

Combinational chemotherapy treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,540
App. No.
12/760,673
Granted
Dec 31, 2013
Kind
B2
Abstract

Disclosed is a composition comprising a therapeutically effective amount of (a) at least one compound from the group of 5-fluorouracil, 5-fluorodeoxyuridine, capecitabine or a prodrug of such compounds; and (b) 5-hydroxymethyl-2′-deoxyuridine, or a prodrug of such compound, as well as kits comprising such composition and methods of use thereof for treating neoplasia.

Claims (17)

1. A method of treating neoplasia in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of:

a) at least one compound selected from the group consisting of 5-Fluorouracil, 5-Fluorodeoxyuridine and capecitabine or other prodrug of 5-fluorouracil; and

b) 5-hydroxymethyl-2′-deoxyuridine, or a prodrug thereof.

2. The method of claim 1 , wherein said compounds of a) and b) are administered sequentially.

3. The method of claim 1 , wherein said compounds of a) and b) are administered simultaneously.

4. The method of claim 1 , wherein said neoplasia is a solid or liquid tumor.

5. The method of claim 4 , wherein said solid tumor is selected from the group consisting of colon cancer, pancreatic cancer and lung cancer.

6. The method of claim 1 , wherein said neoplasia is a refractory tumor.

7. The method of claim 1 , further comprising an agent selected from the group consisting of microtubule-stabilizing agents, microtubule-disruptor agents, alkylating agents, anti-metabolites, epidophyllotoxins, antineoplastic enzymes, topoisomerase inhibitors, inhibitors of cell cycle progression, and platinum coordination complexes.

8. The method of claim 1 , consisting of the administration of 5-Fluorouracil and 5-hydroxymethyl-2′-deoxyuridine.

9. The method of claim 1 , consisting of the administration of 5-Fluorodeoxyuridine and 5-hydroxymethyl-2′-deoxyuridine.

10. A composition comprising:

a) at least one of the compounds selected from the group consisting of 5-Fluorouracil, 5-Fluorodeoxyuridine and capecitabine or other prodrug of 5-fluorouracil; and

b) 5-hydroxymethyl-2′-deoxyuridine or a prodrug thereof and a pharmaceutically acceptable carrier.

11. A composition comprising heterodinucleoside phosphates consisting of 5-Fluorodeoxyuridine and 5-hydroxymethyl-2′-deoxyuridine.

12. A kit for the treatment of neoplasia comprising the composition of claim 10 .

13. The kit of claim 12 , further comprising buffers, containers, and instructional materials.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: THE FOX CHASE CANCER CENTER FOUNDATION
To: THE INSTITUTE FOR CANCER RESEARCH
Reel/Frame 053562/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2011
From: MATSUMOTO, YOSHIHIRO
To: FOX CHASE CANCER CENTER
Reel/Frame 027324/0093 →